Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

In Ho Song

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
Nanoscale|October 12, 2018
Anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosisSeong Jae Kang, Hwa Yeon Jeong, Min Woo Kim, et al.
ACR Open Rheumatology|May 15, 2024
Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 TrialFilip Van den Bosch, Atul Deodhar, Denis Poddubnyy, et al.
Biomaterials|June 4, 2016
Hybridization-based aptamer labeling using complementary oligonucleotide platform for PET and optical imagingJun Young Park, Tae Sup Lee, In Ho Song, et al.
Annals of the Rheumatic Diseases|November 5, 2020
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritisRoy M Fleischmann, Ricardo Blanco, Stephen Hall, et al.
Annals of the Rheumatic Diseases|March 24, 2012
Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trialIn-Ho Song, Christian E Althoff, Hildrun Haibel, et al.
Annals of Coloproctology|September 6, 2019
Long-term Transanal Excision Outcomes in Patients With T1 Rectal Cancer: Comparative Analysis of Radical ResectionYunghuyn Hwang, Yong Sik Yoon, Jun Woo Bong, et al.
Clinical and Experimental Dermatology|May 3, 2024
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trialStephen Tyring, Angela Moore, Akimchi Morita, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 1, 2021
Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label ExtensionAtul Deodhar, Désirée van der Heijde, Joachim Sieper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2019
Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma ModelIn Ho Song, Mun Sik Jeong, Hyo Jeong Hong, et al.
Lancet (London, England)|July 31, 2022
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trialAtul Deodhar, Filip Van den Bosch, Denis Poddubnyy, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Nanoscale|October 12, 2018
Anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosisSeong Jae Kang, Hwa Yeon Jeong, Min Woo Kim, et al.
ACR Open Rheumatology|May 15, 2024
Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 TrialFilip Van den Bosch, Atul Deodhar, Denis Poddubnyy, et al.
Biomaterials|June 4, 2016
Hybridization-based aptamer labeling using complementary oligonucleotide platform for PET and optical imagingJun Young Park, Tae Sup Lee, In Ho Song, et al.
Annals of the Rheumatic Diseases|November 5, 2020
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritisRoy M Fleischmann, Ricardo Blanco, Stephen Hall, et al.
Annals of the Rheumatic Diseases|March 24, 2012
Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trialIn-Ho Song, Christian E Althoff, Hildrun Haibel, et al.
Annals of Coloproctology|September 6, 2019
Long-term Transanal Excision Outcomes in Patients With T1 Rectal Cancer: Comparative Analysis of Radical ResectionYunghuyn Hwang, Yong Sik Yoon, Jun Woo Bong, et al.
Clinical and Experimental Dermatology|May 3, 2024
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trialStephen Tyring, Angela Moore, Akimchi Morita, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 1, 2021
Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label ExtensionAtul Deodhar, Désirée van der Heijde, Joachim Sieper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2019
Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma ModelIn Ho Song, Mun Sik Jeong, Hyo Jeong Hong, et al.
Lancet (London, England)|July 31, 2022
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trialAtul Deodhar, Filip Van den Bosch, Denis Poddubnyy, et al.
Pageof 11